ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $80.00 Consensus PT from Brokerages

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has received an average rating of “Buy” from the four brokerages that are covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $80.00.

ANIP has been the topic of a number of recent research reports. Capital One Financial initiated coverage on ANI Pharmaceuticals in a research report on Friday, March 15th. They set an “overweight” rating and a $80.00 price objective on the stock. HC Wainwright upped their price objective on ANI Pharmaceuticals from $73.00 to $83.00 and gave the stock a “buy” rating in a research report on Monday, March 4th. Guggenheim increased their target price on ANI Pharmaceuticals from $70.00 to $77.00 and gave the company a “buy” rating in a report on Tuesday, March 5th. Finally, Truist Financial increased their target price on ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a “buy” rating in a report on Friday, March 1st.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP opened at $66.30 on Tuesday. ANI Pharmaceuticals has a 52 week low of $36.99 and a 52 week high of $70.81. The company has a fifty day simple moving average of $64.23 and a two-hundred day simple moving average of $58.42. The company has a quick ratio of 2.81, a current ratio of 3.57 and a debt-to-equity ratio of 0.66. The company has a market cap of $1.40 billion, a price-to-earnings ratio of 78.93 and a beta of 0.79.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. ANI Pharmaceuticals had a return on equity of 18.06% and a net margin of 3.86%. As a group, equities analysts anticipate that ANI Pharmaceuticals will post 3.55 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, CEO Nikhil Lalwani sold 28,965 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $65.52, for a total transaction of $1,897,786.80. Following the transaction, the chief executive officer now owns 444,981 shares of the company’s stock, valued at $29,155,155.12. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, SVP Chad Gassert sold 20,000 shares of the firm’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $67.25, for a total value of $1,345,000.00. Following the completion of the sale, the senior vice president now owns 253,226 shares in the company, valued at $17,029,448.50. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Nikhil Lalwani sold 28,965 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $65.52, for a total transaction of $1,897,786.80. Following the sale, the chief executive officer now owns 444,981 shares of the company’s stock, valued at $29,155,155.12. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 138,536 shares of company stock valued at $9,013,167. 12.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of ANIP. Ranger Investment Management L.P. increased its stake in shares of ANI Pharmaceuticals by 254.5% during the 2nd quarter. Ranger Investment Management L.P. now owns 445,157 shares of the specialty pharmaceutical company’s stock worth $23,963,000 after purchasing an additional 319,601 shares in the last quarter. Rubric Capital Management LP grew its stake in ANI Pharmaceuticals by 32.8% in the 4th quarter. Rubric Capital Management LP now owns 1,125,000 shares of the specialty pharmaceutical company’s stock worth $62,032,000 after acquiring an additional 277,989 shares during the period. Invesco Ltd. grew its stake in ANI Pharmaceuticals by 185.4% in the 3rd quarter. Invesco Ltd. now owns 339,735 shares of the specialty pharmaceutical company’s stock worth $19,725,000 after acquiring an additional 220,690 shares during the period. BlackRock Inc. grew its stake in ANI Pharmaceuticals by 9.9% in the 2nd quarter. BlackRock Inc. now owns 2,133,100 shares of the specialty pharmaceutical company’s stock worth $114,825,000 after acquiring an additional 191,402 shares during the period. Finally, Vanguard Group Inc. grew its stake in ANI Pharmaceuticals by 13.8% in the 4th quarter. Vanguard Group Inc. now owns 1,288,972 shares of the specialty pharmaceutical company’s stock worth $71,074,000 after acquiring an additional 156,594 shares during the period. 76.05% of the stock is currently owned by institutional investors and hedge funds.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.